All In Biotech

NDA 017862 · Hikma

Reglan

Metoclopramide Hydrochloride · Injection

NovelPriority reviewDiscontinued

Last checked: Nov 20, 2026Latest source record: Feb 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1979

Feb 7, 1979

Approved uses

6

Original approval plus efficacy supplements

Registered trials

192

38 Phase 3, 6 recruiting

FAERS reports

26,247

21,440 serious, 2,766 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 28, 1987 Supplement 21 · Efficacy
  • Jul 5, 1983 Supplement 20 · Efficacy
  • Jun 28, 1982 Supplement 6 · Efficacy
  • Feb 19, 1982 Supplement 9 · Efficacy
  • Jan 22, 1981 Supplement 3 · Efficacy
  • Feb 7, 1979 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • REGLAN · METOCLOPRAMIDE HYDROCHLORIDE EQ 5MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • REGLAN · METOCLOPRAMIDE HYDROCHLORIDE EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Metoclopramide" as an intervention, any sponsor and status, largest first.

All 192 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • tardive dyskinesia6,603
  • extrapyramidal disorder3,954
  • dystonia2,529
  • nausea2,484
  • vomiting1,729
  • diarrhoea1,368
  • pain1,327
  • fatigue1,283
  • incorrect drug administration duration1,264
  • dyspnoea1,208
  • asthenia1,039
  • headache1,023

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004525
2005571
2006566
2007563
2008594
2009832
20101,178
20114,035
20123,769
20131,211
2014934
2015843
2016980
20171,062
2018916
20191,028
2020966
2021925
20221,156
20231,049
2024976
2025912
2026649

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Reglan (Metoclopramide HCl)

2024 spending

$68K

Beneficiaries

33

122 claims

Per beneficiary

$2,051

$3.86 per unit

View as table
YearSpending
2020$106,782
2021$94,620
2022$88,032
2023$88,394
2024$67,698

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,551 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.